



Peacock, A., Leung, J., Larney, S., Colledge, S., Hickman, M., Rehm, J., Giovino, G. A., West, R., Hall, W., Griffiths, P., Ali, R., Gowing, L., Marsden, J., Ferrari, A. J., Grebely, J., Farrell, M., & Degenhardt, L. (2018). Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. *Addiction*, 113(10), 1905-1926.
<https://doi.org/10.1111/add.14234>

Peer reviewed version

Link to published version (if available):
[10.1111/add.14234](https://doi.org/10.1111/add.14234)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

SUPPLEMENTARY MATERIALS

Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.

Hindocha, C^{1*}, Freeman, T.P^{1,2}, Grabski, M^{1,3}, Stroud, J.B¹, Crudgington, H¹, Davies, A.C.¹, Das, R.K¹, Lawn, W¹, Morgan, C.J.A^{1,4}, Curran, H.V.¹

¹Clinical Psychopharmacology Unit, University College London, WC1E 7HB

²National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8BB, United Kingdom.

³School of Experimental Psychology, University of Bristol, 12a Priory Road, BS81TU, Bristol.


⁴Psychopharmacology and Addiction Research Centre, University of Exeter, UK

Running Head: CANNABIDIOL FOR TOBACCO WITHDRAWAL

Correspondence to: Chandni Hindocha, Clinical Psychopharmacology Unit, University College London, 1-19 Torrington Place, London, WC1E 7HB. Email: c.hindocha@ucl.ac.uk

Supplementary Method

Participant recruitment



Supplementary Figure 1: flow diagram for study recruitment and assessments. The final sample included 30 participants who completed all three sessions.

Procedure

Supplementary table 1: Schedule of assessments on the satiated and abstinent sessions.

SATIATED		ABSTINENT	
TIME		TIME	
0	Arrival	0	Arrival
12	MPSS QSU [1]	5	MPSS QSU HR BP [1]
30	Cigarette	10	Drug administration
35	MPSS QSU [2]	70	MPSS QSU HR BP [2]
60	Visual Probe	130	MPSS QSU HR BP [3]
68	PRT	190	Visual Probe
75	MPSS QSU [3]	198	PRT
-	-	200	MPSS QSU [4]

Supplementary Results

Time since last smoked

There was a significant main effect of abstinence ($F(1,29)= 3289.03$, $p<.001$, $\eta^2p=.99$) where on the satiated session, participants last smoked M: 0.41 (SD: 0.40) hours previously, in comparison to abstinent. There was no main effect of drug ($F(1,29)=0.18$, $p=.675$, $\eta^2p=.006$). Participants last smoked M: 10.97 (SD:0.96) hours previously on the CBD session and M:11.03 (SD:0.95) on the PBO session.

CO

There was a significant main effect of abstinence ($F(1,29)=167.83$, $p<.001$, $\eta^2p=.84$) which shows CO was higher in the satiated condition (M: 17.73 ppm SD: 6.63) than in the abstinent conditions. There was no main effect of drug ($F(1,29)=6.13$, $p=.019$, $\eta^2p=.17$) where CO was 4.27ppm (SD:2.23) for CBD and 4.17 (SD:2.69) for PBO. Thus abstinence was biologically verified.

MPSS

Amount of time spent with urge

Pre-drug time spent with urges was significantly greater under abstinent than satiated sessions ($F(1,29)=27.96$, $p<.001$, $\eta^2p=.49$) suggesting abstinence increased the amount of time spent with urges to smoke. There was no difference between CBD and PBO, pre-drug administration ($p=0.536$; JZS BF in support of the null= 5.86). To investigate if CBD attenuated craving in comparison to placebo on abstinent sessions, we conducted an ANOVA that showed a main effect of time ($F(3,87)=8.65$, $p<.001$, $\eta^2p=.23$) which showed that time spent with urges decreased from T1 (3.17, 95% CI 2.79-3.64) to T2 (2.40, 95% CI 1.97-2.82), and increased from T2 to T3 (2.80, 95% CI 2.38-3.22). However there was no effect of drug ($p=1.00$; JZS BF in support of the null= 7.08) There was no drug x time interaction ($F(2, 68)=.25$, $p=.81$, $\eta^2p=0.00$).

Strength of urges

Pre-drug strength of urges was significantly greater under abstinent than satiated sessions ($F(1,29)=26.26$, $p<.001$, $\eta^2p=.48$) suggesting abstinence increased the strength of urges. There was no difference between CBD and PBO, pre drug administration ($p=0.879$; JZS BF in support of the null= 6.99). To investigate if CBD attenuated craving in comparison to placebo on abstinent sessions, we conducted an ANOVA that showed a main effect of time ($F(3,87)=4.33$, $p=.007$, $\eta^2p=.13$) which showed that time spent with urges decreased significantly from T1 (2.92, 95% CI 2.58-3.25) to T2 (2.40, 95% CI 2.02-2.78), and increased from T2 to T3 (2.48, 95% CI 2.10-2.87) and T4 (2.73, 95% CI 2.31-3.16). However there was no effect of drug ($p=.61$; JZS BF in support of the null= 6.20) There was no drug x time interaction ($F(3, 87)=0.65$, $p=0.58$, $\eta^2p=0.02$).

Side effects

Strong Drug effect: There was no main effect of drug ($F(1,29)=.80$, $p=.379$, $\eta^2p=.03$) confirmed by Bayesian analysis (JZS BF: 4.82), time ($F(2,58)=.37$, $p=.695$, $\eta^2p=.01$), or drug x time interaction ($F(2,58)=2.18$, $p=.123$, $\eta^2p=.07$).

Good Drug effect: There was no main effect of drug ($F(1,29)=.10$, $p=.922$, $\eta^2p=.00$) confirmed by Bayesian analysis (JZS BF:7.04), time ($F(2,58)=2.76$, $p=.072$, $\eta^2p=.09$), or drug x time interaction ($F(2,58)=2.18$, $p=.123$, $\eta^2p=.07$).

Willing to take drug again: There was no main effect of drug ($F(1,29)=2.35, p=.136, \eta^2p=.08$) confirmed by Bayesian analysis (JZS BF: 2.35), time ($F(2,58)=0.42, p=.661, \eta^2p=.01$), or drug x time interaction ($F(2,58)=1.12, p=.306, \eta^2p=.040$).

Like drug effect: There was no main effect of drug ($F(1,29)=.01, p=.947, \eta^2p=.00$) confirmed by Bayesian analysis (JZS BF: 7.06) or drug x time interaction ($F(2,58)=.03, p=.968, \eta^2p=.00$). There was a main effect of time ($F(2,58)=3.53, p=.036, \eta^2p=.11$) which showed liking decreased over time.

I have a stomach ache: There was no main effect of drug ($F(1,29)=.00, p=.957, \eta^2p=.00$) confirmed by Bayesian analysis (JZS BF:7.07), time ($F(2,58)=.01, p=.988, \eta^2p=.000$), or drug x time interaction ($F(2,58)=1.44, p=.245, \eta^2p=.05$).

I have a headache: There was a drug x time interaction ($F(2,58)=3.17, p=.049, \eta^2p=.099$).

Exploration of the interaction showed no significant pairwise comparisons. There was no main effect of drug ($F(1,29)=.04, p=.839, \eta^2p=.00$) confirmed by Bayesian analysis (JZS BF:6.93), or time ($F(2,58)=.80, p=.456, \eta^2p=.03$).